PE20231573A1 - Anticuerpos biespecificos cd47-cd38 - Google Patents

Anticuerpos biespecificos cd47-cd38

Info

Publication number
PE20231573A1
PE20231573A1 PE2023001174A PE2023001174A PE20231573A1 PE 20231573 A1 PE20231573 A1 PE 20231573A1 PE 2023001174 A PE2023001174 A PE 2023001174A PE 2023001174 A PE2023001174 A PE 2023001174A PE 20231573 A1 PE20231573 A1 PE 20231573A1
Authority
PE
Peru
Prior art keywords
seq
binds
human
bispecific antibodies
binding portion
Prior art date
Application number
PE2023001174A
Other languages
English (en)
Inventor
Laure Bouchez
Blandine Pouleau
Marie-Anges Doucey
Elie Dheilly
Stanislas Blein
Cian Stutz
Carole Estoppey
Jeremy Loyau
Thierry Monney
Camile Grandcelment
Stefano Sammicheli
Original Assignee
Ichnos Sciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichnos Sciences SA filed Critical Ichnos Sciences SA
Publication of PE20231573A1 publication Critical patent/PE20231573A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Referida a un anticuerpo biespecifico que comprende al menos dos porciones de union, al menos una de las cuales se une a la CD38 humana y al menos una de las cuales se une a la CD47 humana, donde dicha porcion de union que se une a la CD38 humana comprende un conjunto de CDRs seleccionado del grupo que comprende: SEQ ID NO: 103, SEQ ID NO: 163, SEQ ID NO: 223; SEQ ID NO: 117, SEQ ID NO: 177, SEQ ID NO: 237; SEQ ID NO: 121; SEQ ID NO: 181, SEQ ID NO: 241 y la porcion de union que se une a la CD47 humana comprende un conjunto de CDRs que comprende: SEQ ID NO: 75, SEQ ID NO: 135, SEQ ID NO: 195. Dichos anticuerpos son utiles para tratar enfermedades autoinmunitarias y proliferativas y en particular tipos de cancer tales como neoplasias malignas hematologicas y tumores solidos.
PE2023001174A 2020-09-18 2021-09-17 Anticuerpos biespecificos cd47-cd38 PE20231573A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20197033 2020-09-18
PCT/EP2021/075687 WO2022058539A1 (en) 2020-09-18 2021-09-17 Cd47-cd38 bispecific antibodies

Publications (1)

Publication Number Publication Date
PE20231573A1 true PE20231573A1 (es) 2023-10-04

Family

ID=72603323

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001174A PE20231573A1 (es) 2020-09-18 2021-09-17 Anticuerpos biespecificos cd47-cd38

Country Status (15)

Country Link
US (1) US20220089767A1 (es)
EP (1) EP4214231A1 (es)
JP (1) JP2023542907A (es)
KR (1) KR20230088370A (es)
CN (1) CN116648463A (es)
AR (1) AR123548A1 (es)
AU (1) AU2021344635A1 (es)
CA (1) CA3192465A1 (es)
CL (1) CL2023000786A1 (es)
CO (1) CO2023004698A2 (es)
IL (1) IL301330A (es)
MX (1) MX2023003192A (es)
PE (1) PE20231573A1 (es)
TW (1) TW202227497A (es)
WO (1) WO2022058539A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240132615A1 (en) * 2022-05-05 2024-04-25 Ichnos Sciences SA CD3/BCMA/CD38 Trispecific Antibodies
WO2023220641A2 (en) * 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
RU2015102845A (ru) 2010-02-23 2015-06-10 Санофи АНТИТЕЛА К ИНТЕГРИНУ α2 И ИХ ПРИМЕНЕНИЯ
CN108285488B (zh) 2011-03-25 2023-01-24 伊克诺斯科学公司 异二聚体免疫球蛋白
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途

Also Published As

Publication number Publication date
CL2023000786A1 (es) 2023-09-15
AR123548A1 (es) 2022-12-14
AU2021344635A9 (en) 2024-02-08
US20220089767A1 (en) 2022-03-24
CN116648463A (zh) 2023-08-25
CA3192465A1 (en) 2022-03-24
EP4214231A1 (en) 2023-07-26
IL301330A (en) 2023-05-01
CO2023004698A2 (es) 2023-07-21
KR20230088370A (ko) 2023-06-19
WO2022058539A1 (en) 2022-03-24
MX2023003192A (es) 2023-06-09
JP2023542907A (ja) 2023-10-12
AU2021344635A1 (en) 2023-04-27
TW202227497A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
EA201990781A1 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
PE20231573A1 (es) Anticuerpos biespecificos cd47-cd38
UY39024A (es) Proteínas terapéuticas de unión a dll4
EA201891428A1 (ru) Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли
MX2022001831A (es) Anticuerpos terapeuticos y sus usos.
EA201792522A1 (ru) Лечение злокачественной опухоли с помощью комбинированной блокады сигнальных путей pd-1 и cxcr4
EA201691858A1 (ru) Композиции антител для лечения опухолей
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
EA201790986A1 (ru) Антитела к cd73 и их применения
BR112023002895A2 (pt) Anticorpos anti-ror1 e proteínas de ligação biespecíficas relacionadas
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
RU2018112649A (ru) Композиция для лечения рака, объединяющая анти-cd26 антитело и другое противораковое средство
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
BR112023019484A2 (pt) Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3
MX2023004089A (es) Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12.
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
MX2022006289A (es) Tratamiento de canceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12.
MX2022000779A (es) Anticuerpo monoclonal anti-vegf humanizado.
BR112021020873A2 (pt) Métodos para tratamento de câncer renal com um anticorpo anti-psma/cd3
EA201992522A1 (ru) КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
MX2022007353A (es) Anticuerpos novedosos ddr1 y sus usos.
MX2022002363A (es) Sistema receptor de antígeno quimérico y usos de este.
EA202091978A1 (ru) Биспецифические связывающие агенты и варианты их применения
AR110819A1 (es) Anticuerpos anti-fgfr (receptor del factor de crecimiento de fibroblastos) y métodos de uso